Fernanda Wagner

Ms. Fernanda Wagner

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2025 in Biochem
Verified
Journal Article
Open access
PDF file
VCVítor Campos
Vítor Campos
AYAngela Theresa Zuffo Yabrude
Angela Theresa Zuffo Yabrude
RLRenata Delarue Toniolo Lima
Renata Delarue Toniolo Lima
FWFernanda Wagner
Fernanda Wagner
Henrique Nunes Pereira OlivaHenrique Nunes Pereira Oliva
Henrique Nunes Pereira Oliva
Background/Objectives: Passiflora (passionflower), traditionally used for anxiety and insomnia, is primarily known for GABAergic modulation. However, evidence suggests broader neuropharmacological actions. This review aimed to systematically explore non-GABAergic mechanisms of Passiflora. Methods: We performed a systematic review following PRISMA Guidelines (PROSPERO: CRD420251028681). PubMed/Medline, PsycINFO, Embase, Web of Science, and Scopus were searched for original research on non-GABA neurobiological mechanisms of Passiflora species (P. incarnata, P. edulis, P. caerulea, P. actinia, P. foetida). Studies were screened and assessed for eligibility, and data on design, Passiflora preparation, mechanisms, and main findings were extracted. Results: Thirteen studies revealed diverse non-GABAergic actions. Passiflora modulates opioidergic and nicotinic cholinergic systems (relevant to analgesia), monoaminergic pathways (affecting dopamine, norepinephrine, serotonin), and the glutamatergic system (offering neuroprotection via NMDA receptor inhibition). It also exhibits significant anti-inflammatory and antioxidant effects (reducing cytokines, activating Nrf2) and modulates the HPA axis (reducing stress hormones). Other mechanisms include gut microbiota modulation and metabolic effects. Conclusions: Passiflora’s therapeutic potential extends beyond GABA, involving multiple neurotransmitter systems and neuroprotective, anti-inflammatory, antioxidant, and HPA axis-regulating activities. This multi-target profile likely contributes to its clinical efficacy in conditions like anxiety, pain, and stress, potentially with a favorable side-effect profile. Further research, including mechanistic studies and clinical trials with relevant biomarkers, is needed to fully elucidate its complex pharmacology.

Verified
Journal Article
Open access
PDF file
JGJoão Ismael Budelon Gonçalves
João Ismael Budelon Gonçalves
FLFernanda Muller Lermen
Fernanda Muller Lermen
JGJúlia Budelon Gonçalves
Júlia Budelon Gonçalves
GZGabriele Zanirati
Gabriele Zanirati
DMDenise Cantarelli Machado
Denise Cantarelli Machado
DMDaniel Marinowick
Daniel Marinowick
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has posed unprecedented challenges to global health systems, particularly among vulnerable populations such as the elderly. Understanding the interplay between anthropometric markers, molecular profiles, and disease severity is crucial for effective clinical management and intervention strategies. We conducted a cohort study comprising 43 elderly COVID-19 patients admitted to São Lucas Hospital, PUCRS, Brazil. Anthropometric measurements, including calf circumference (CC) and abdominal circumference (AC), were assessed alongside molecular analyses of peripheral blood samples obtained within 48 h of hospital admission. Sociodemographic data were collected from electronic medical records for comprehensive analysis. Our findings revealed a possible relationship between overweight status, increased abdominal adiposity, and prolonged hospitalization duration, alongside heightened disease severity. We also found no significant correlations between BMI, vitamin D levels, and clinical outcomes. Elevated oxygen requirements were observed in both normal and overweight individuals, with the latter necessitating prolonged oxygen therapy. Molecular analyses revealed changes in the inflammatory profile regarding the outcome of the patients. Our study highlights the critical importance of both anthropometric and molecular markers in predicting disease severity and clinical outcomes in elderly individuals with COVID-19.

Verified
Journal Article
Open access
PDF file
FGFabiana Amaral Guarienti
Fabiana Amaral Guarienti
FXFernando Antonio Costa Xavier
Fernando Antonio Costa Xavier
MFMateus Duarte Ferraz
Mateus Duarte Ferraz
FWFernanda Wagner
Fernanda Wagner
DMDaniel Marinowick
Daniel Marinowick
DMDenise Cantarelli Machado
Denise Cantarelli Machado
Regardless of the containment of the SARS-CoV-2 pandemic, it remains paramount to comprehensively understand its underlying mechanisms to mitigate potential future health and economic impacts, comparable to those experienced throughout the course of the pandemic. The angiotensin-converting enzyme 2 (ACE2) provides anchorage for SARS-CoV-2 binding, thus implicating that ACE and ACE2 might contribute to the variability in infection severity. This study aimed to elucidate predisposing factors influencing the disease course among people infected by SARS-CoV-2, focusing on angiotensin-converting enzyme (ACE) and ACE2 polymorphisms. Notably, despite similar demographics and comorbidities, COVID-19 patients exhibit substantial differences in prognosis. Genetic polymorphisms in ACE and ACE2 have been implicated in disease progression, prompting our investigation into their role in COVID-19 evolution. Using next-generation sequencing (NGS), we analyzed ACE and ACE2 genes in a sample group comprising six subjects infected by SARS-CoV-2. Our findings revealed a correlation between specific polymorphisms and COVID-19 outcomes. Specifically, ACE and ACE2 intronic deletions were observed in all deceased patients, suggesting a potential association with mortality. These results highlight the significance of genetic factors in shaping the clinical course of COVID-19, emphasizing the importance of further research into the impact of genetic variations on COVID-19 severity.

28 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
FGFabiana Amaral Guarienti
Fabiana Amaral Guarienti
FXFernando Antonio Costa Xavier
Fernando Antonio Costa Xavier
MFMateus Duarte Ferraz
Mateus Duarte Ferraz
FWFernanda Wagner
Fernanda Wagner
DMDaniel Marinowick
Daniel Marinowick
DMDenise Cantarelli Machado
Denise Cantarelli Machado
Regardless of the SARS-CoV-2 pandemic containment, it remains paramount to comprehensively understand its underlying mechanisms to mitigate potential future health and economic impacts, comparable to those experienced throughout the course of the pandemic. The angiotensin-converting enzyme 2 (ACE2) provide anchorage for SARS-CoV-2 binding, thus implicating that ACE and ACE2 might contribute to the variability in infection severity. This study aimed to elucidate predisposing factors influencing the disease course among people infected by SARS-CoV-2, focusing on angiotensin-converting enzyme (ACE) and ACE2 polymorphisms. Notably, despite similar demographics and comorbidities, COVID-19 patients exhibit substantial differences in prognosis. Genetic polymorphisms in ACE and ACE2 have been implicated in disease progression, prompting our investigation into their role in COVID-19 evolution. Using next-generation sequencing (NGS), we analyzed ACE and ACE2 genes in a sample group comprising six subjects infected by SARS-CoV-2. Our findings revealed a correlation between specific polymorphisms and COVID-19 outcomes. Specifically, ACE and ACE2 intronic deletions were observed in all deceased patients, suggesting a potential association with mortality. These results highlight the significance of genetic factors in shaping the clinical course of COVID-19, emphasizing the importance of further research into the impact of genetic variations on COVID-19 severity.

2 June 2026 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
ASAna Gabriely Sales da Silva
Ana Gabriely Sales da Silva
MSMariana Veiga e Silva
Mariana Veiga e Silva
BOBeatriz Castanha de Oliveira
Beatriz Castanha de Oliveira
FWFernanda Wagner
Fernanda Wagner
MVMarcos Antonio Dias Vilela
Marcos Antonio Dias Vilela
COClaudia Maria Costa de Oliveira
Claudia Maria Costa de Oliveira